Cell and Gene Therapy, Department of Biomedicine, Basel University Hospital, Hebelstrasse 20, Basel, CH-4031, Switzerland.
Biochem Soc Trans. 2011 Dec;39(6):1644-8. doi: 10.1042/BST20110650.
Therapeutic angiogenesis is an attractive strategy to treat patients suffering from peripheral or coronary artery disease. VEGF (vascular endothelial growth factor-A) is the fundamental factor controlling vascular growth in both development and postnatal life. The interplay between the VEGF and Notch signalling pathway has been recently found to regulate the morphogenic events leading to the growth of new vessels by sprouting. Angiogenesis can also take place by an alternative process, i.e. intussusception or vascular splitting. However, little is known about its role in therapeutic angiogenesis and its molecular regulation. In the present article, we briefly review how VEGF dose determines the induction of normal or aberrant angiogenesis and the molecular regulation of sprouting angiogenesis by Notch signalling, and compare this process with intussusception.
治疗性血管生成是一种有吸引力的策略,可用于治疗患有外周或冠状动脉疾病的患者。VEGF(血管内皮生长因子-A)是控制发育和出生后生命中血管生长的基本因素。最近发现,VEGF 和 Notch 信号通路之间的相互作用通过发芽来调节导致新血管生长的形态发生事件。血管生成也可以通过替代过程发生,即内陷或血管分裂。然而,关于其在治疗性血管生成中的作用及其分子调节知之甚少。在本文中,我们简要回顾了 VEGF 剂量如何决定正常或异常血管生成的诱导,以及 Notch 信号对发芽血管生成的分子调节,并将这一过程与内陷进行了比较。